2021 Research Forum
U-M College of Pharmacy
March 17, 2021 - 6:00-7:30pm
Posters will be presented in one of two 45-minute sessions (6:00-6:45 pm or 6:45-7:30 pm). The presenters' poster time is located below the "Chat with Presenter" button. Poster presentations will include the following groups:
• Pharmacy Residents
• Honors BSPS students
• McGlone Award Nominees (P4 students)
• PharmD P4 students
For questions during the event, please contact Holly Jablonski at email@example.com.
POSTER #B01: Combined Ribosome Engineering and UV Mutagenesis for Production of Cryptic Secondary Metabolites in Streptomyces sp. F181
Linwei Yang, Jonida Trako, Ashootosh Tripathi, Ph.D.
POSTER #B02: Comprehensive Assessment of the Effect of Genetic Variation on Concentrations of Tamoxifen and its Metabolites
Yuanhuang Chen, Lauren Marcath, PharmD, Thomas Helland, PhD, Daniel Hertz, PharmD, PhD
POSTER #B03: United States Pharmacopeia Disintegration Test Optimization for In-Vivo Relevance
Zebedee Miller, Dr. Gregory Amidon
POSTER #B04: Cytoplasmic Construction of Functional Mechanopharmaceutical Devices Within the Cells of Living Organisms
Jiayi Nie, Andrew Willmer, Gustavo Rosania
POSTER #B05: Differential tissue expression of antiviral nucleotide prodrug activating enzymes and SARS-CoV-2 related host proteins provide insights into the drug discovery and application for COVID-19.
Yanling Xue, Jiapeng Li, Xin wen Wang, Jian Shi, Haojie Zhu
POSTER #B06: Systemic Delivery of STING Agonists by Liposomal Coordination Polymer
Xiaoyue Shi，Xiaoqi Sun，James Moon
POSTER #B07: NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Inhibitors - Review, Discovery and Outlook
Zixian Zhu, Nouri Neamati
POSTER #B08: Development and Evaluation of [18F]FNP-59, a Cholesterol Radiotracer
Wade P. Winton1,2, Allen F. Brooks2, Jenelle Stauff2, Janna Arteaga2, Bradford Henderson2, David M. Raffel2, Ka Kit Wong2, Benjamin L. Viglianti2,3, Peter J. H. Scott2,4,5
Methods: FNP-59 standard and precursor were synthesized over 8 and 6 steps respectively. The radiosynthesis of [18F]FNP-59 was achieved in 2 steps over 2 hours with a radiochemical yield of 44.1±18.6 mCi. Preclinical imaging was conducted in both female Sprague Dawley rat and female Watanabe heritable hyperlipidemic rabbit. Biodistribution experiments were conducted with 2 male and 2 female Sprague Dawley rats sacrificed at 5 timepoints and each of their organs weighed and measured for radioactivity. Dosimetry estimates were then calculated based on this biodistribution data using OLINDA/EXM 2.0. Finally, preliminary human imaging was undertaken under an IND approved by the FDA.
Results: Preclinical imaging and biodistribution in rats demonstrated high uptake in the adrenal glands and low interference from the liver and other abdominal organs. Imaging in rabbits, which have a gallbladder and significantly different lipid handling properties, indicated reduced adrenal uptake and higher liver and gallbladder uptake. Translation to humans demonstrated further reductions in adrenal uptake and high liver and gallbladder uptake. Studies utilizing alternate administration strategies to alter [18F]FNP-59 trafficking by altering its incorporation into lipoproteins are ongoing.
POSTER #B09: Biosynthetic diversification of a moroidin peptides for biomedical characterization
Jun Zhou, Roland D. Kersten
POSTER #MG01: A Single-Center Comparison of Decitabine ± Venetoclax or FLAG in the Treatment of Secondary Acute Myeloid Leukemia
Devon S. Stonerock, Morgan Homan, Bernard L. Marini, Anthony J. Perissinotti, Dale Bixby, Kristin Pettit, Patrick W. Burke, Lydia L. Benitez
POSTER #MG02: Vancomycin Dosing in Hepatic Cirrhosis Patients: Use Doses-Less when Hepatic Duress?
Ryan Larson, Tara Bracken, Randolph Regal
Objective: Using a calculated “trough to dose ratio”, or TDR (trough level/mg/kg/24h), we wanted to compare vancomycin dosing requirements in cirrhotic patients with those of non-cirrhotic matched cohorts.
Methods: We conducted a single-centered, retrospective chart review of cirrhotic and non-cirrhotic control patients admitted to Michigan Medicine who received IV vancomycin between January 2016 and February 2020. All patients had to have serum creatinines less than or equal to 1.2 mcg/ml at baseline and at least one steady-state trough to qualify. For comparison, both groups were further allocated to three matched age groups (30-39; 40-49; 50-59).
Results: Among the 200 total patients (150 non-cirrhotic patients and 50 cirrhotic), 43 patients were between the ages of 30-39 (86% non-cirrhotic, 14% cirrhotic), 55 between the ages of 40-49 (78% non-cirrhotic, 22% cirrhotic), and 102 between the ages of 50-59 (69% non-cirrhotic, 31% cirrhotic). Sex was evenly distributed within each age group. Baseline characteristics such as serum creatinine (SCr), weight, and mean age were also similar. TDRs for cirrhotics were 50, 45, and 32% higher than their controls, respectively. However, due to the small sample size, only age 50-59 had statistically significantly higher TDR values than the non-cirrhotic patients (95% CI, 0.05-0.27; P<0.006). Supratherapeutic vancomycin troughs (>20 mg/L) also occurred more frequently in our cirrhotic cohort (22%) when compared to our control group (8%).
Conclusions: In this retrospective study comparing vancomycin dosing standardized by mg/kg/24h in cirrhotic patients and non-cirrhotic patients with similar baseline characteristics, patients with cirrhosis achieved roughly 30-50% higher trough levels when compared to non-cirrhotic cohorts receiving the same dose. These results suggest that making empiric dose reductions in cirrhotic patients when using standard vancomycin dosing nomograms is a reasonable approach.
POSTER #MG03: Evaluating the incidence of pneumocystis jirovecii pneumonia in pediatric patients
Michelle Nguyen, Julia Brown, PharmD., Madeleine King, PharmD.
POSTER #MG04: Development of a Pediatric Biopharmaceutical Classification System
Varsha Bhatt-Mehta, Hannah Hammoud, Gordon Amidon
POSTER #MG05: Feasibility of Retrospective Outcomes Assessment for Infectious Disease Patients Treated under Expanded Access at Michigan Medicine
Ibtihal Makki, Rivka Siden PharmD, Misty Gravelin MPH
1. Jarow JP, Lurie P, Ikenberry SC, Lemery S. Overview of FDA’s Expanded Access Program for Investigational Drugs. Ther Innov Regul Sci. 2017;51:177–9. 2. Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals. Br J Clin Pharmacol 2020;86:1819-26. 3. Reagan-Udall Foundation for the Food and Drug Administration. Public Meeting Report Leveraging Real-World Treatment Experience from Expanded Access Protocols. https://reaganudall.org/sites/default/files/2019-12/Leveraging%20Real-World%20Treatment%20Experience%20from%20Expanded%20Access%20Protocols%20Report.pdf. Accessed 30 November 2020.
POSTER #MG06: State-Wide Quality Improvement Addressing Overutilization of Neurokinin-1 Receptor Antagonists
Michelle K. Azar; Kelly Procailo; Louise Bedard; Emily R. Mackler
POSTER #MG07: The impact of pharmacogenetic testing in mood disorders: real world outcomes from a single-center study
David Schapiro, Jennifer Irish Pharm.D., Vicki Ellingrod Pharm.D., Kristen Ward Pharm.D.
POSTER #MG08: Evaluating the implementation of premedications prior to pegaspargase infusions in pediatric acute lymphoblastic leukemia patients
Audrey Yeiter, Morgan Homan PharmD, Julia Brown PharmD
POSTER #MG09: Evaluating coenzyme Q10 therapy in participants experiencing statin associated muscle symptoms
Wilson Chen, BS, Heather M. Ochs-Balcom, PhD, Georgirene D. Vladutiu, PhD, Jasmine A. Luzum, PharmD, PhD
POSTER #MG10: Pharmacogenomic Approach To Optimize Antihypertensive Therapy: Single-dose PK Study of Trandolapril in Healthy Volunteers
HeeJae Choi, PharmD Candidate; Haojie Zhu, PhD; Lucy Her, PharmD; Xinwen Wang, PhD
POSTER #PD01: Quitting smoking and current asthma diagnosis associated respectively with housing status
Krestina Bednarz, PharmD Candidate 2021, Chad Compagner, PharmD Candidate 2021, Sarah E. Vordenberg, PharmD, MPH, BCACP, Antoinette B. Coe, PharmD, PhD, Karen B. Farris, PhD
POSTER #PD03: The risk of oral or topical antimicrobials for acne in the development of Clostridium difficile colitis (CDI)
Sydney VanDorf (University of Michigan PharmD Candidate 2021) and Peggy Carver PharmD, FCCP, FIDP (University of Michigan College of Pharmacy)
POSTER #PD04: Drug Repurposing and Expanded Access Case Studies of Clofazimine for Nontuberculous Mycobacterial Infection
Madeleine Davies; Misty Gravelin, MPH; Samuel Handelman, PhD; Kevin Weatherwax; Kevin Gregg, MD; Jonathan Sexton, PhD
POSTER #PD05: Evaluation of an intentional one-time interprofessional interaction between pharmacy and medical students and the impact on the increase of interprofessional knowledge
Christina Tang, PharmD Candidate
Method: Participants included 2nd year pharmacy students and 3rd year medical students enrolled in University of Michigan during the 2018-2019 academic year. Students were required to have an in-person interaction for a geriatric patient case. Separate patient interviews were conducted by each discipline and the gathered information was compared during the interaction. Students completed a post-interaction survey. Qualitative data from this instrument for these IPE experiences was de-identified and quantified into different categories to allow measurable outcomes which were then prospectively analyzed. Overall response rates and discipline-specific response rates were calculated and compared by theme.
Results : During the 2018-2019 academic year, 138 medical students and 86 pharmacy students participated in this study for a total of 224 participants. The positive impact of the interaction on patient care was reported by 166 students of the 224 participants. Learning about the other profession's training and education was most surprising to students, especially so for medical students compared to pharmacy students (33% vs 24%). Future interactions between the two disciplines seemed more likely to happen with 43% of medical students more likely to consult pharmacists. Of note, 41% of pharmacy students showed a desire to increase interprofessional practice either through increased communication with patients and doctors or more collaboration with health professionals compared to 22% of medical students.
Conclusion: Overall, implementing a one-time intentional IPE experience to healthcare students increased their IPE knowledge, enhanced their understanding of the other discipline’s role and training, and created a positive perception of working together in the future.
POSTER #PD06: Quitting smoking and current asthma diagnosis associated respectively with housing status
Krestina Bednarz, PharmD Candidate 2021, Chad Compagner, PharmD Candidate 2021, Sarah E. Vordenberg, PharmD, MPH, BCACP, Antoinette B. Coe, PharmD, PhD, Karen B. Farris, PhD
POSTER #PR01: Comparison of outcomes for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients undergoing chimeric antigen receptor (CAR) T-cell therapy vs autologous stem cell transplant (ASCT)
Brian Bazzell, PharmD; Madeleine Ochs, PharmD; Gianni Scappaticci, PharmD, BCOP; Anthony Perissinotti, PharmD, BCOP; Bernard Marini, PharmD, BCOP; Victoria Nachar, PharmD, BCOP
To address this question, we performed a single-center, retrospective, propensity-score matched cohort study of R/R DLBCL patients treated at the University of Michigan who exhibited PR to salvage therapy (assessed via PET-CT) and then proceeded to ASCT or CAR T therapy from January 2015 to December 2020. Cohort 1 includes patients who went to ASCT after salvage, while Cohort 2 includes patients who received CAR T therapy. Exclusion criteria include patients < 18 years old and those with insufficient records. Data related to demographics, upfront treatment, salvage treatment, toxicity, time to ASCT/CAR T infusion, and survival outcomes will be collected. The primary endpoint is progression-free survival, defined as time from treatment until relapse or death. Time-to event analyses were assessed via the Kaplan-Meier method and log-rank test.
POSTER #PR02: Incidence and Risk Factors for Bacterial Infection in Newly Diagnosed Multiple Myeloma Patients (NDMM) Undergoing Treatment with Bortezomib, Lenalidomide, and Dexamethasone (RVd)
Anisa Bici, PharmD; Victoria Nachar, PharmD, BCOP; Matthew Pianko, MD
Objective: To characterize the risk of bacterial infection and identify risk factors for bacterial infection in NDMM patients receiving standard therapy with RVd. Methods: Patients with NDMM undergoing induction with RVd at Michigan Medicine from January 2014 until January 2020 will be included. Patients will be followed for at least 12 weeks during induction therapy until the time of maintenance therapy or autologous-stem cell transplant (ASCT). Patients that start with Cyclophosphamide + Bortezomib + Dexamethasone for 1-2 cycles and switch to RVd before transplant or maintenance will also be included. Patients who are less than 18 years of age, receiving an investigational agent in combination with RVd, or undergoing treatment with RVd but switch to another treatment before ASCT will be excluded. Patients will be divided into two cohorts based on if they do or do not experience a bacterial infection during induction. Data that will be collected include: age, gender, eGFR, treatment regimen, comorbidities, ISS/R-ISS staging, cytogenetics risk at diagnosis, M protein, Serum β-2-microglobulin, IgG, IgA, IgM, absolute neutrophil count, previous infection in 30 days preceding, baseline bone disease, infectious prophylaxis received. The primary outcome will be to establish risk factors for early bacterial infection in NDMM patients undergoing induction with RVd. Secondary outcome includes assessing early mortality rates.
Results/Conclusions: TEAMM trial demonstrated febrile episodes in 19% of patients receiving levofloxacin and in 27% of patients receiving placebo. The rate of febrile episodes was much lower in our study, even in those who experienced a true bacterial infection. Our study found a higher incidence of febrile episodes in patients that experienced a bacterial infection (P=0.003) but no difference in the incidence of deaths from infectious complications (p=1.000). Overall incidence of true bacterial infection in NDMM patients receiving induction with RVd was low despite many patients receiving no bacterial prophylaxis. The most common types of infections included pneumonia and UTI and there was a very low incidence of sepsis/bacteremia. A multivariate analysis will identify risk factors for bacterial infection which will help assess if antibiotic prophylaxis should be considered for certain high-risk patients. Our study has many limitations including its retrospective design, small sample size, missing data on bacterial infections if treated at an outside facility and selection bias. Future directions include a multivariate analysis and a multicenter trial with an increased patient population.
POSTER #PR04: Review of Varenicline Prescribing Practices at a Mid-Level VA
Kirsten Carstarphen, PharmD, MPH, Marissa Dunham, PharmD, BCACP, Petra Flanagan, PharmD
POSTER #PR06: Retrospective evaluation of opioid use in the inpatient acute leukemia population
Kaylee A Clark, PharmD*; Lydia Benitez, PharmD, BCOP; Bernard Marini, PharmD, BCOP; Anthony Perissinotti, PharmD, BCOP
Objective: Evaluate opioid prescribing for patients with acute leukemias at the University of Michigan Health System to determine the overall burden and impact of long-term opioid use in acute leukemia patients initially naïve to opioids.
Methods: This was a single center, retrospective matched cohort study of adult patients undergoing induction therapy for newly diagnosed acute leukemias from June 2014 to June 2020. This study is IRB exempt approved by the Michigan Medicine IRB. Patients were excluded if patient record is incomplete or for opioid use prior to admission, defined as any opioid on their home medication list. Data was collected characterizing demographics, comorbidities, hematologic disease, induction chemotherapy received, pain regimen utilized outside of treatment plan (if applicable), and opioid duration post-induction therapy (if applicable). The primary endpoint was the percentage of opioid-naive patients on chronic opioid therapy, defined as opioids prescribed 3 months after acute leukemia induction therapy. Secondary endpoints include proportion of opioid naïve patients prescribed opioids for pain, risk factors for long-term opioid use, percentage of patients on opioid therapy at 3, 6, and/or 9 months after induction therapy.
Results/Conclusions: non-applicable, research in progress
POSTER #PR07: Efficacy, Cost and Toxicity of Fixed Versus Weight-Based Dosing of Pembrolizumab and Nivolumab
Taylor Coe-Eisenberg, PharmD, Samantha Pike, PharmD Candidate
POSTER #PR08: Correlation of medication regimen complexity in the ICU to internal pharmacist workload measurements
Sydnee Cohen, PharmD*; Melissa Pleva, PharmD, BCPS, BCNSP, BCCCP; Karl Renius, PharmD, BCPS, BCOP; Bruce W. Chaffee, PharmD, FASHP; James Miller, PharmD, BCCCP
POSTER #PR09: Prevalence of NCCN Guideline Adherence and its Impact on Length of Stay
Jacqueline Dela Pena, PharmD, Michael Smith, PharmD, BCPS
Methods: This study will be a single-center, retrospective chart review of adult patients with active cancer and admitted to Michigan Medicine for pain. Patients must receive at least one dose of opioids within 24 hours upon admission. Patients admitted into the intensive care unit, an admission stay less than 24 hours, expired during the encounter, or with a current or past diagnosis of opioid use disorder will be excluded. Data collected from medical records will include demographics, primary cancer site, presence of metastases, type of opioid and dose ordered, daily average of opioid utilization in morphine milligram equivalents, presence of nausea, vomiting and/or constipation, pain scores, and length of stay. The primary outcome will be the percentage of orders that are guideline adherent and the length of stay measured in days. Secondary outcomes will include pain scores and incidence of opioid related adverse events.
Results/Conclusions: Data is currently being collected.
POSTER #PR10: Assessment of Pharmacist Management of the Perioperative Process for Patients on Anticoagulation Therapy Undergoing Catheterization Procedure
Mary J. Elder, PharmD; Elizabeth Renner, PharmD, BCPS, BCACP, CACP; Erin Mouland, PharmD, CACP; Nghi Ha, PharmD, MPH, BCPS, CACP
POSTER #PR11: Adherence and Cost Implications of Aortic Dissection Management Guidelines
Jalen R. Evans, PharmD, Simona O. Butler, PharmD, BCPS, Angela M. Clark, PharmD, BCPS
POSTER #PR12: Provider Confidence in Pain Management and Opioid Prescribing in the Inpatient Setting
Colin Finley, PharmD, Michael Smith, PharmD, BCPS, and Jillian DiClemente, PharmD
POSTER #PR13: Assessment of a decrease in ethanol lock frequency on central line-associated blood stream infection (CLABSI) rates in home pediatric intestinal failure total parenteral nutrition (TPN)-dependent patients
Mon-Yee J. Fung (PharmD), Meghan A. Arnold (MD FACS), Nicholas Dillman (PharmD), M. Luisa Partipilo (PharmD BCNSP)
Methods: This longitudinal chart review is a single group cohort non-inferior study utilizing a pre-post intervention design of 13 pediatric patients followed by providers from the Children’s Intestinal Rehabilitation Program (ChIRP) at Michigan Medicine. Pre- and post-intervention data will include the rates of CLABSI per 1000 catheter days, the microorganisms causing the CLABSI, and reported CVAD complications. From a previous a previous study, the basis of absolute difference in rates of CLABSI per 1000 catheter days with one-weekly ethanol lock solution therapy versus placebo, the non-inferiority margin for the difference in rates of CLABSI per 1000 catheter days was defined as 73%.
Results: The mean baseline infection rate when our patients were using daily ethanol lock solution was 1.01 CLABSI per 1000 catheter days. This baseline increased to a mean of 1.06 CLABSI per 1000 catheter days when these patients were switched over to three times weekly ethanol lock solution. The absolute mean difference of -0.05 or 5% increase in CLABSI per 1000 days (95% CI -2.26 to 2.15, p = 0.47) was non-significant demonstrating non-equivalence between three-times-weekly and daily ethanol lock solution therapy. There was, also, no significant difference in catheter repair or replacement between the two regimens (p = 0.11 and 0.41, respectively).
Conclusion: As a pilot assessment of a change in protocol focusing on a single group cohort, we were unable to conclude that three times weekly is non-inferior to daily ethanol lock solution therapy. A study design with a larger sample size over an extended time period beyond 6 months may help demonstrate if times weekly is equivalent to daily ethanol lock solution therapy.
POSTER #PR14: Comparing the Efficacy and Tolerance of New Hepatitis C Agents at Michigan Medicine: Can We ‘C’ a Difference?
Lisa M. Giangardella, PharmD; Randolph Regal, PharmD; Karin Durant, PharmD; Rima A. Mohammad, PharmD, FCCP, BCPS; Sarah Tischer, PharmD, BCPS
Methods: This study was an IRB approved, retrospective chart review of patients 18 years of age or older who have been diagnosed with HCV. In addition, these patients were prescribed one of the five HCV agents from July 1, 2019 through June 30, 2020 in the outpatient setting at Michigan Medicine (MM). This report was generated through EPIC MiChart and contained pertinent information including patient name, medication ordered, order date and time, pharmacy, and the primary payer. The primary outcome was the successful completion rates (SCR) between the agents studied. This was defined as patients who had an HCV Polymerase Chain Reaction (PCR) Quantitative test done during therapy and the lab resulted as "Target Not Detected." Secondary outcomes include: patients who experienced a side effect and SCR amongst those who utilized MM Specialty Pharmacy which were both analyzed utilizing a Chi Square analysis. Other outcomes included: distribution of the use of the agents, and when assessed, characterize time to clearance of HCV. Since these agents have been found to be relatively well tolerated in previous studies, the hypothesis is there are no differences in successful completion rates between the agents studied.
Results/Conclusions: Data collection and analysis are currently ongoing. Results will be presented at the the virtual poster session.
POSTER #PR15: Stop in the Name of Stewardship: Adherence to Antibiotic Stop Times in the Neonatal Intensive Care Unit
Kaitlynn Hughes PharmD, Erin Munsel PharmD, Courtney Doellner PharmD
POSTER #PR17: Development and Implementation of Strategies to Improve Pharmacy Technician Recruitment and Retention
David J. Jackson, PharmD; Mike D. Kraft, PharmD, BCNSP; Anna LeRoy, MSHROD, PHR; Stan S. Kent, RPh, MS, FASHP
POSTER #PR19: Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Renal Transplant Recipients
Trung Q. Ky, PharmD; Abduraham Barakat; Rawan Harb; Nathan Laviste; Jeong Park, MS, PharmD, FCCP, FAST, BCPS
Stable RTRs who were at least three years post-transplant and taking immediate-release tacrolimus were eligible. Patients were excluded if they had fewer than three tacrolimus levels within 8 months from protocol implementation. Primary outcome was the time to intervene on tacrolimus levels outside the goal range 4-8 ng/ml. Secondary outcomes included tacrolimus time in therapeutic range (TTR), coefficient of variance (CV), and protocol adherence.
Of the 1712 levels (from 174 RTRs), 259 levels (15.1%) were out-of-range. The average time to intervention was significantly different between the Pre-Arm and the Post-Arm (58.8±56.6 vs. 45.6±50.6 hours, respectively; P=0.048). Excluding 50 provider interventions in the Post-Arm, nurses took 42.3±48.9 hours to intervention (P=0.027), -16.5 hours (95%CI: -31.0-1.9 hours) shorter than the provider interventions in the Post-Arm. The TTR was 89.3±17.6% vs 89±19.4% (P=0.816) and CV was 0.20±0.16 vs 0.18±0.11 (P=0.358) in the Pre-Arm and Post-Arm, respectively. Nurses adhered to the protocol 56.2% of the time.
Implementation of a standardized TDM protocol improved efficiency for stable RTRs in the outpatient setting by reducing time to respond to tacrolimus trough levels by 16.5 hours. The difference can also be considered clinically significant, given the twice-daily dosing of tacrolimus. The intrapatient variability in tacrolimus levels was not negatively affected by the TDM protocol. Further analysis is needed to improve the protocol adherence.
POSTER #PR20: Safety and Efficacy of GLP-1 Receptor Agonists in Combination with SGLT-2 Inhibitors in a VA Population with Type 2 Diabetes Mellitus
Lauren McCulley, PharmD; Kathryn Hurren, PharmD, CDCES
POSTER #PR21: Multicenter Comparison of Re-Induction Regimens in Relapsed/Refractory Ph- ALL: Results from Michigan Medicine
Madeleine A. Ochs, PharmD; Brian G. Bazzell, PharmD; Bernard L. Marini, PharmD, BCOP; Lydia L. Benitez, PharmD, BCOP; Anthony J. Perissinotti, PharmD, BCOP
Objective(s): Compare the overall survival of chemotherapy versus novel therapies in patients with R/R Ph- ALL.
Methods: This study will be a multi-center (U of M, MSK, and UNC), retrospective propensity score matched cohort study of adult patients receiving 2nd line therapy for first relapse or primary refractory B-cell, Ph-negative ALL from January 1, 2012 date to August 1, 2020. Cohort 1 will consist of patients with R/R Philadelphia chromosome negative ALL who received chemotherapy re-induction (ie: hyper-cvad, MOAD, Larson/CALGB-9511, etc). Cohort 2 will consist of patients who received novel therapies (blinatumomab or inotuzumab). Exclusion criteria include Ph+ ALL, patients who only received HyperCVAD part A prior to 2nd line therapy, and patient with incomplete records. Data will be collected on demographics, disease related characteristics, initial therapy, re-induction therapy, toxicity, post re-induction therapy, and outcomes. The primary endpoint is overall survival. Time-to-event analyses (EFS and OS) will be compared using the Kaplan-Meier method and long-rank test.
Results: Non-applicable, research in progress.
Conclusions/Discussion: Non-applicable, research in progress.
POSTER #PR22: Impact of transporter pharmacogenetics on CNS tumor response
Carl Okerberg, Bernie Marini, Amy Pasternak
POSTER #PR23: Examining the use of warfarin surrounding patient falls in an inpatient rehabilitation setting
Emily Sahagian, PharmD; Kristin Phillips, PharmD; Christine Cigolle, MD, MPH; Neil Alexander, MD, MS; Robert Hogikyan, MD, MPH
POSTER #PR24: Hyperkalemia management in pediatric patients - shifting to a protocolized approach
Andrea Setiawan, PharmD; Elizabeth VanWert, PharmD, BCPS; Nada Saad, PharmD; & Emily Supenia, PharmD, BCPS
POSTER #PR25: Evaluating Pneumocystis jiroveci pneumonia prophylaxis in lung transplant recipients
Jessica Sharkey, Katie McMurry, Jamie Park, Christie Carlson, Kevin Gregg, Daniel Kaul, Dennis Lyu, Linda Fitzgerald
POSTER #PR26: Comparison of Cystatin C versus Creatinine Based Equations to Estimate Vancomycin Population Pharmacokinetics
Andrew Smith, Ken DeBacker, Manjunath Pai
POSTER #PR27: Assessment of Flowsheet Integration on Renal Dosing Optimization
Steven Stettner, PharmD; Karl Renius PharmD, BCPS, BCOP; Jerod Nagel PharmD, BCIDP
Methods: The Institutional Review Board at Michigan Medicine approved this observational prospective study. Patients at least 18 years of age and receiving at least one of the pre-specified subset of medications on the renal dose policy while admitted from September 2020 to January 2021 were included. The scoring tool fires if any of the following occurs: patient’s serum creatinine or calculated creatinine clearance crosses a dosing threshold on the renal dosing policy or an order is signed or verified for a medication on the renal dose policy and the patient has abnormal renal function. Each time the scoring tool is triggered, the patient’s current creatinine clearance, serum creatinine, and medication related information are populated onto a flowsheet. The primary outcome will be the incidence of medication verification with non-concordant renal dosing pre- and post-implementation of the new renal workflow. Secondary outcomes will include the duration of non-concordant medication orders, dose related adverse drug events for non-optimized patients, and reported medication errors within the study time frame.
POSTER #PR28: Bacteremia in Hematology Patients: Impact of Duration of Antibiotic Therapy on Clinical Outcomes
Ryan Sutherlan, PharmD; Lydia Benitez-Colon, PharmD, BCOP; Anthony J. Perissinotti PharmD, BCOP; Jason Pogue, PharmD, BCPS, AQID, BCIDP; Bernard L. Marini, PharmD, BCOP
The guidelines regarding the treatment and prevention of bacteremia in leukemia patients lack substantial data to support their recommended antibiotic treatment durations and seem to be a result of consensus opinion. In studies of other patient populations presenting with bacteremias, antibiotic courses less than ten days compared to standard courses of antibiotics evidenced no significant differences in microbiological cure or mortality.
The objective of this study is to assess the outcomes of shorter courses of antibiotic therapy compared to standard courses in leukemia patients presenting with a bacteremia from an enterobacteriaceae pathogen.
POSTER #PR29: Assessing the Impact of CYP2D6 Phenotype on Ondansetron and Palonosetron Toxicity
Carolanne Wartman, PharmD; Amy Pasternak, PharmD, BCPS
POSTER #PR30: Evaluation of Newer Diabetes Medication Use and Hypoglycemic Risks in Older Veterans
Lauren D. Williams, PharmD; Kristin Phillips, PharmD; Pearl Lee, MD; Christine Cigolle, MD
POSTER #PR31: Comparison of the Effects of Dexmedetomidine vs. Propofol on Time to Extubation in Select Cardiac Surgery Patients
Roberta Wilson, PharmD, Simona Butler, PharmD, Angela Clark, PharmD, Anna Dubovoy, MD, Amy Geltz, MS, RN, Jonathan Haft, MD, Jeremy Wolverton
POSTER #PR32: Comparison of Transplant Pharmacist Interventions Between Telehealth and Clinic Visits
Jiashan Xu, PharmD; Amy Thompson, PharmD, BCACP; Linda Fitzgerald, PharmD, BCPS; Tracy Licari, MS, PA-C; Katie McMurry, PharmD; Sarah Tischer, PharmD, BCPS
POSTER #PR33: Evaluating the Latency Period in Women with Preterm Premature Rupture of Membranes (PPROM) with GBS Coverage and Erythromycin or Azithromycin
Caitlyn A. Young, PharmD*; Lauren D. Leader PharmD, BCPS; Elizabeth S. Langen, MD